6 Biotechnology Stocks to Sell Now

6 Biotechnology Stocks to Sell Now

This week, 6 Biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Alexion Pharmaceuticals, Inc. (ALXN) gets weaker ratings this week as last week’s D drops to a F. Alexion Pharmaceuticals, Inc. engages in the innovation, development, and commercialization of life-transforming therapeutic products for treating patients with severe and ultra-rare disorders in the United States, Europe, Latin America, Japan, and the Asia Pacific. The company also gets F’s in operating margin growth. For more information, get Portfolio Grader’s complete analysis of ALXN stock.

Vertex Pharmaceuticals Incorporated (VRTX) is having a tough week. The company’s rating falls from a D to a F. Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of VRTX stock.

This week, Acorda Therapeutics, Inc.’s (ACOR) rating worsens to a F from the company’s D rating a week ago. Acorda Therapeutics, Inc. is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The company also gets F’s in operating margin growth, earnings growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of ACOR stock.

Kura Oncology, Inc. (KURA) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of KURA stock.

Prana Biotechnology Ltd Sponsored ADR (PRAN) declines this week from a C to a D. Prana Biotechnology Ltd Sponsored ADR is an Australian biotechnology company which researches and develops therapeutic drugs used for treatment of Alzheimer’s Disease and other age-related degenerative disorders such as Parkinson’s Disease and cataracts. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of PRAN stock.

Capricor Therapeutics, Inc. (CAPR) slips from a C to a D this week. The company also gets F’s in sales growth and free cash flow. For more information, get Portfolio Grader’s complete analysis of CAPR stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/10/6-biotechnology-stocks-to-sell-now-4/.

©2019 InvestorPlace Media, LLC